StockNews.AI
ACET
StockNews.AI
169 days

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

1. Adicet Bio announced two abstracts accepted for SITC 2025 presentations. 2. The conference could enhance visibility and interest in ACET's therapies.

2m saved
Insight
Article

FAQ

Why Bullish?

Presentation at a significant conference increases investor interest. Historically, similar announcements have positively impacted biotech stock prices.

How important is it?

The upcoming presentation could lead to investor interest and validate ACET's research, vital for stock performance.

Why Long Term?

Visibility from presentations can lead to future partnerships or investments, enhancing ACET's pipeline development.

Related Companies

SITCBMYJNJ
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A. Details of the poster presentation are as follows: Abstract Ti.

Related News